1. Home
  2. PMM vs PROF Comparison

PMM vs PROF Comparison

Compare PMM & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Managed Municipal Income Trust

PMM

Putnam Managed Municipal Income Trust

HOLD

Current Price

$6.23

Market Cap

258.7M

Sector

Finance

ML Signal

HOLD

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$5.93

Market Cap

238.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMM
PROF
Founded
1989
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
258.7M
238.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PMM
PROF
Price
$6.23
$5.93
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
111.4K
232.7K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
4.68%
N/A
EPS Growth
N/A
25.89
EPS
0.23
1.41
Revenue
N/A
$16,098,000.00
Revenue This Year
N/A
$92.40
Revenue Next Year
N/A
$64.10
P/E Ratio
$27.22
$4.57
Revenue Growth
N/A
50.73
52 Week Low
$5.70
$3.92
52 Week High
$6.52
$8.95

Technical Indicators

Market Signals
Indicator
PMM
PROF
Relative Strength Index (RSI) 54.06 45.70
Support Level $6.07 $5.81
Resistance Level $6.36 $5.98
Average True Range (ATR) 0.09 0.49
MACD 0.02 0.08
Stochastic Oscillator 83.74 49.19

Price Performance

Historical Comparison
PMM
PROF

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: